26-Feb-2026 3:05 PM CST - Business Wire Vir Biotechnology to Participate in Upcoming Investor Conferences Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026, at 3:10 p.m. ET/12:10 p.m. PT in Boston, Massachusetts. Leerink Partners Global Healthcare Conference: Marianne De Backer, M
23-Feb-2026 4:14 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstr
9-Feb-2026 3:05 PM CST - Business Wire Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results for the fourth quarter and full year ended December 31, 2025. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical co
12-Jan-2026 7:00 AM CST - Business Wire Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving the combination therapy of tobevibart, an investigational neutralizing monoclonal antibody (mAb), and elebsiran, an investigational small interfering RNA (siRNA), showed increased and sustained viral suppression of HDV RNA versus treatment with the antibody alone in p
5-Jan-2026 3:05 PM CST - Business Wire Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology
19-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
7-Nov-2025 8:00 AM CST - Business Wire Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
5-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quarter demonstrated exceptional execution across our clinical portfolio," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "We completed ECLIPSE 1 enrollment approximately two months ahead of schedule and continue to see strong momentum across ECLIPSE 2 and 3, positioning us well fo
26-Feb-2026 3:05 PM CST - Business Wire Vir Biotechnology to Participate in Upcoming Investor Conferences Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026, at 3:10 p.m. ET/12:10 p.m. PT in Boston, Massachusetts. Leerink Partners Global Healthcare Conference: Marianne De Backer, M
23-Feb-2026 4:14 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstr
9-Feb-2026 3:05 PM CST - Business Wire Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results for the fourth quarter and full year ended December 31, 2025. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical co
12-Jan-2026 7:00 AM CST - Business Wire Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving the combination therapy of tobevibart, an investigational neutralizing monoclonal antibody (mAb), and elebsiran, an investigational small interfering RNA (siRNA), showed increased and sustained viral suppression of HDV RNA versus treatment with the antibody alone in p
5-Jan-2026 3:05 PM CST - Business Wire Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology
19-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
7-Nov-2025 8:00 AM CST - Business Wire Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.
5-Nov-2025 3:05 PM CST - Business Wire Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quarter demonstrated exceptional execution across our clinical portfolio," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "We completed ECLIPSE 1 enrollment approximately two months ahead of schedule and continue to see strong momentum across ECLIPSE 2 and 3, positioning us well fo
